REFERENCES
2. National Cancer Institute. SEER cancer stat facts: pancreatic cancer. Available from: https://seer.cancer.gov/statfacts/html/pancreas.html. [Last accessed on 12 Oct 2026].
3. Huang B, Huang H, Zhang S, et al. Artificial intelligence in pancreatic cancer. Theranostics. 2022;12:6931-54.
4. Korfiatis P, Suman G, Patnam NG, et al. Automated artificial intelligence model trained on a large data set can detect pancreas cancer on diagnostic computed tomography scans as well as visually occult preinvasive cancer on prediagnostic computed tomography scans. Gastroenterology. 2023;165:1533-46.e4.
5. Chen PT, Wu T, Wang P, et al. Pancreatic cancer detection on CT scans with deep learning: a nationwide population-based study. Radiology. 2023;306:172-82.
6. Sethi N, Varma CV, Reddy SS. Artificial intelligence in pancreatic cancer: applications in early detection, tumor staging, and survival prediction - a comprehensive review. Clin Transl Oncol. 2026;28:4308-27.
7. Collins GS, Moons KGM, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378.
8. Wolff RF, Moons KGM, Riley RD, et al. ; PROBAST Group. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 2019;170:51-8.
9. Mongan J, Moy L, Kahn CE. Checklist for artificial intelligence in medical imaging (CLAIM): a guide for authors and reviewers. Radiol Artif Intell. 2020;2:e200029.
10. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26:565-74.
11. Lekadir K, Frangi AF, Porras AR, et al. FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare. BMJ. 2025;388:e081554.
12. Vasey B, Nagendran M, Campbell B, et al. Reporting guideline for the early stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI. BMJ. 2022;377:e070904.
13. Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18:2-11.
14. Wang J, Ashraf Ganjouei A, Romero-Hernandez F, et al. A computer vision algorithm to predict superior mesenteric artery margin status for patients with pancreatic ductal adenocarcinoma. Ann Surg. 2026;283:834-40.
15. Zhao T, Wen Y, Chen Y, et al. Utility of a CAD model for estimation of vascular involvement and R0 resection in pancreatic ductal adenocarcinoma. Int J Surg. 2025;111:7829-41.
16. Zhang Y, Zhang H, Yang Y, et al. A clinically validated 3D deep learning approach for quantifying vascular invasion in pancreatic cancer. NPJ Digit Med. 2025;9:79.
17. Bereska JI, Janssen BV, Nio CY, et al. ; Pancreatobiliary and Hepatic Artificial Intelligence Research (PHAIR) consortium. Artificial intelligence for assessment of vascular involvement and tumor resectability on CT in patients with pancreatic cancer. Eur Radiol Exp. 2024;8:18.
18. Zhou Y, Wang J, Zhang SL, et al. A CT radiomics-based risk score for preoperative estimation of intraoperative superior mesenteric-portal vein involvement in pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2023;30:1206-16.
19. Yimamu A, Li J, Zhang H, et al. Computed tomography and guidelines‐based human–machine fusion model for predicting resectability of the pancreatic cancer. J Gastroenterol Hepatol. 2023;39:399-409.
20. Guo R, Zhang M, Zhu H, et al. A clinician-centric intelligent method towards reliable pancreatic cancer vascular invasion assessment: a retrospective, multi-centre study. Lancet Reg Health West Pac. 2026;71:101890.
21. Rhu J, Oh N, Choi GS, et al. 3D auto-segmentation of pancreas cancer and surrounding anatomical structures for surgical planning. Int J Surg. 2025;111:6715-24.
22. Mellado S, Vega EA, Yamane K, et al. Deep-learning virtual superior mesenteric artery modeling for risk stratification in pancreas surgery. Ann Surg Oncol. 2026;33:1627-35.
23. Sguinzi R, Vidal J, Poroes F, et al. 3D modeling to predict vascular involvement in resectable pancreatic adenocarcinoma. Heliyon. 2025;11:e41473.
24. Shi J, Cui R, Wang Z, et al. Deep learning HRNet FCN for blood vessel identification in laparoscopic pancreatic surgery. NPJ Digit Med. 2025;8:235.
25. Takayama M, Takeuchi M, Tomita K, et al. Artificial intelligence-assisted estimation of superior mesenteric artery dissection extent during robotic pancreatoduodenectomy. HPB. 2026;28:976-86.
26. Fraunhoffer N, Hammel P, Conroy T, et al. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Ann Oncol. 2024;35:780-91.
27. Nicolle R, Bachet JB, Harlé A, et al. Prediction of adjuvant gemcitabine sensitivity in resectable pancreatic adenocarcinoma using the GemPred RNA signature: an ancillary study of the PRODIGE-24/CCTG PA6 clinical trial. J Clin Oncol. 2024;42:1067-76.
28. Harada GK, Park J, Peterson N, et al. Predicting benefit of neoadjuvant chemotherapy and elective nodal irradiation in pancreatic adenocarcinoma: a supervised machine learning approach. Cancer Med. 2025;14:e71447.
29. Yang Q, Mao Y, Han Y, et al. Noninvasive computed tomography-based quantification of tumor fibrosis predicts pancreatic cancer response to gemcitabine/nab-paclitaxel. Research. 2025;8:0937.
30. Hendifar AE, Krishna V, Krishna V, et al. Development and validation of a computational histology artificial intelligence-powered predictive biomarker for selection of chemotherapy in advanced pancreatic cancer. J Clin Oncol. 2026;44:2496-506.
31. Abreu de Carvalho LF, Gryspeerdt F, Ceelen W, et al. Prediction of surgical resectability after FOLFIRINOX chemotherapy for borderline resectable and locally advanced pancreatic cancer (PeRFormanCe): a multicenter prospective trial - trial protocol. BMC Surg. 2025;25:204.
32. Wainberg ZA, Link JM, Premji A, et al. Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial. Nat Commun. 2026;17:2232.
33. Wakiya T, Ishido K, Kimura N, et al. Prediction of massive bleeding in pancreatic surgery based on preoperative patient characteristics using a decision tree. PLoS One. 2021;16:e0259682.
34. Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161:584-91.
35. Ashraf Ganjouei A, Romero-Hernandez F, Wang JJ, et al. A machine learning approach to predict postoperative pancreatic fistula after pancreaticoduodenectomy using only preoperatively known data. Ann Surg Oncol. 2023;30:7738-47.
36. Màlyi A, Bronsert P, Schilling O, et al. Postoperative pancreatic fistula risk assessment using digital pathology based analyses at the parenchymal resection margin of the pancreas - results from the randomized multicenter RECOPANC trial. HPB. 2025;27:393-401.
37. Liang K, Miao Q, Jing Y, et al. Integrative deep learning analysis of 2D and 3D body composition features for predicting postoperative pancreatic fistula after distal pancreatectomy. Ann Med. 2025;57:2597067.
38. Ahmed KS, Issaka SM, Marcinak CT, et al. Machine learning-driven modeling to predict postdischarge venous thromboembolism after pancreatectomy for pancreas cancer. Ann Surg Oncol. 2025;32:4085-93.
39. Daibo S, Homma Y, Ohya H, et al. Novel machine-learning model for predicting lymph node metastasis in resectable pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2025;9:161-8.
40. Chen X, Wang W, Jiang Y, Qian X. A dual-transformation with contrastive learning framework for lymph node metastasis prediction in pancreatic cancer. Med Image Anal. 2023;85:102753.
41. Guan X, Liu J, Xu L, Jiang W, Wang C. A CT-based deep learning radiomics nomogram for early recurrence prediction in pancreatic cancer: a multicenter study. Ann Surg Oncol. 2025;32:7567-76.
42. Wu L, Cen C, Ouyang D, et al. Interpretable machine learning model for predicting early recurrence of pancreatic cancer: integrating intratumoral and peritumoral radiomics with body composition. Int J Surg. 2025;111:8198-211.
43. Zhao B, Xia C, Xia T, et al. Development of a radiomics-based model to predict occult liver metastases of pancreatic ductal adenocarcinoma: a multicenter study. Int J Surg. 2024;110:740-9.
44. Zheng S, Liu Y, Troy Teo P, et al. A deep learning model for preoperative risk stratification of pancreatic ductal adenocarcinoma based on genomic predictors of liver metastasis. Eur J Cancer. 2025;226:115608.
45. Zhang Y, Lobo-Mueller EM, Karanicolas P, Gallinger S, Haider MA, Khalvati F. Improving prognostic performance in resectable pancreatic ductal adenocarcinoma using radiomics and deep learning features fusion in CT images. Sci Rep. 2021;11:1378.
46. Kim H, Choi JH, Lim Y, et al. Artificial intelligence-powered spatial analysis of immune phenotypes in resected pancreatic cancer. JAMA Surg. 2025;160:884-92.
47. Gu Q, Liu P, Hu X, Liu J, He Y. Development and validation of a CT-measured body composition radiomics model for prognostic assessment in resected pancreatic adenocarcinoma. Sci Rep. 2025;15:28722.
48. Yoo J, Hyun SH, Lee J, et al. Prognostic significance of 18F-FDG PET/CT radiomics in patients with resectable pancreatic ductal adenocarcinoma undergoing curative surgery. Clin Nucl Med. 2024;49:909-16.
49. Yao J, Cao K, Hou Y, et al. Deep learning for fully automated prediction of overall survival in patients undergoing resection for pancreatic cancer: a retrospective multicenter study. Ann Surg. 2023;278:e68-79.
50. Bhayana R, Nanda B, Dehkharghanian T, et al. Large language models for automated synoptic reports and resectability categorization in pancreatic cancer. Radiology. 2024;311:e233117.
51. U.S. Food and Drug Administration. Artificial intelligence-enabled device software functions: lifecycle management and marketing submission recommendations. Draft Guidance for Industry and Food and Drug Administration Staff. January 2025. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/artificial-intelligence-enabled-device-software-functions-lifecycle-management-and-marketing. [Last accessed on 12 Oct 2026].
52. U.S. Food and Drug Administration. Marketing submission recommendations for a predetermined change control plan for artificial intelligence-enabled device software functions. Guidance for Industry and Food and Drug Administration Staff. August 2025. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial-intelligence. [Last accessed on 12 Oct 2026].
53. Artificial Intelligence Board; Medical Device Coordination Group. AIB 2025-1/MDCG 2025-6: Interplay between the Medical Devices Regulation (MDR), In vitro Diagnostic Medical Devices Regulation (IVDR), and Artificial Intelligence Act (AIA). June 2025. Available from: https://health.ec.europa.eu/document/download/b78a17d7-e3cd-4943-851d-e02a2f22bbb4_en?filename=mdcg_2025-6_en.pdf. [Last accessed on 12 Oct 2026].
54. Müller PC, Erdem S, Kuemmerli C, et al. Artificial intelligence and image guidance in minimally invasive pancreatic surgery: current status and future challenges. Art Int Surg. 2025;5:170-81.
